

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

NCT06972056

| | |
|------------|--------------------|
| Status | RECRUITING |
| Phase | Phase 4 |
| Sponsor | Mayo Clinic |
| Enrollment | 1,335 participants |

Key Eligibility Criteria

Inclusion (10)

- Adults, 18-70 years of age at the time of enrollment
- Migraine with aura, migraine without aura, and/or chronic migraine; according to ICHD-3 diagnostic criteria. (Those with daily or continuous headaches are not excluded.)
- Migraine onset prior to 50 years of age
- Migraine present for at least 12 months at the time of enrollment
- At least four "moderate to severe headache days" per month (by patient self-report and then confirmed during four-week pre-randomization headache diary phase) A "moderate to severe headache day" is defined as a day during which there is a headache of moderate to severe intensity that lasts for at least four hours, or a day on which a migraine-specific acute medication is taken to treat headache.

... and 5 more (see full listing online)

Exclusion (18)

- Contraindications to taking atogepant, propranolol, or topiramate.
- Currently taking atogepant, propranolol, or topiramate*
- Previously took atogepant, propranolol, or topiramate*
- Unwillingness to take atogepant, topiramate, or propranolol.
- Current use of a CGRP-targeting preventive medication or beta-blocker

... and 13 more (see full listing online)

Locations (23 total)

Northern Arizona Healthcare, Flagstaff, Arizona, United States
Mayo Clinic Arizona, Phoenix, Arizona, United States
USC Keck, Los Angeles, California, United States

... and 20 more locations